UNAIDS’ HIV This Week contains a brief on the Scientific Strategic Plan of the Enterprise. The editors note that “a quick read of this forward-looking framework will help you better understand the part that you can play in this global collective undertaking. Together we can succeed in overcoming what some have called the greatest scientific challenge of our time.”
According to a single-patient study published in the October issue of Nature Communications, B-cells and neutralizing antibodies might control HIV levels better than scientists previously suspected. The authors of the study note that the finding could open a new avenue for both preventive and treatment vaccines for HIV. To view the full text of the study, please click here.
Los Alamos National Laboratory announced that one of its researchers, Bette Korber, is part of an international team of investigators working to design and implement the first human trial of a mosaic HIV vaccine candidate. The team is led by Dr. Bart Haynes under the Center for HIV/AIDS Vaccine Immunology (CHAVI). According to Dr.
In an article in Global Health, Seth Berkley of IAVI discussed the role of recent scientific breakthroughs in the elicitation of sufficiently potent antibodies against many of the subtypes of HIV in circulation. According to Berkley, the recent renaissance in AIDS vaccine research and development is the reason the outlook for an AIDS vaccine is more promising today than ever. The full story can be read here.
More than 1,100 individuals from around the world attended AIDS Vaccine 2010 (28 September - 1 October) in Atlanta, Georgia. Information on the meeting, including speaker presentations, webcasts of special sessions and press conferences, photos and much more can be found here: http://www.hivvaccineenterprise.org/conference_archive/2010/index.php.
The U.S. Military HIV Research Program (MHRP) issued a statement on the one-year anniversary of the announcement of the results of RV144, the trial in Thailand that showed the first evidence that a vaccine is able to reduce risk of HIV infection in humans. The statement is available here: http://www.hivresearch.org/news.php?NewsID=193.
AVAC released a statement welcoming the new Global HIV Vaccine Enterprise Scientific Strategic Plan stating that the Plan is "a critical document that the field must implement as part of ongoing efforts to improve coordination, efficiency and transparency to quickly capitalize on recent advances in AIDS vaccine research." The full statement is below.